(April 2, 2019, 1:40 PM EDT) -- TRENTON, N.J. — A New Jersey federal judge on March 29 granted in part and denied in part a motion by three insulin makers to dismiss claims by Medicare claims payers that the drug makers inflated the prices of their diabetes drugs to boost their profits and those of pharmacy benefit managers (PBMs) who hold sway over what drugs health insurance plans will pay for (MSP Recovery Claims, et al. v. Sanofi Aventis U.S. LLC, et al., No. 18-2211, D. N.J., 2019 U.S. Dist. LEXIS 54086)....